Contemporary automated insulin delivery systems in older adults with type 1 diabetes: A systematic review and meta-analysis.

Diabetes Res Clin PractAug 11, 2026 (epub)
Clinical ResearchEndocrinology

Piyush Ratan, Marconi Abreu, Luisa Saldarriaga et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the effectiveness of automated insulin delivery (AID) systems in adults aged 60 years and older with type 1 diabetes. The analysis included nine studies with 8,765 participants. AID use resulted in a pooled mean time in range of 77.95% and a reduction in HbA1c to 6.95%, indicating improved glycemic control without increased hypoglycemia.

Key findings

  • Pooled mean time in range (TIR) was 77.95% (95% CI 75.31-80.59).
  • HbA1c levels decreased to 6.95% (95% CI 6.67-7.24).
  • Time below range (TBR) was 1.35% (95% CI 1.12-1.57).
  • AID use was associated with lower diabetes distress without increased hypoglycemia.

Why it matters

The findings suggest that AID systems can significantly improve glycemic control in older adults with type 1 diabetes, a population often overlooked in diabetes technology discussions. This could enhance patient quality of life and management outcomes.

Source

PubMed · PMID 42580597

Published in Diabetes Res Clin Pract. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.